SAN
103.98
+0.48%↑
SHL.DE
55.4
+0.54%↑
PHIA
24.26
+0.96%↑
SRT3
241.7
-2.89%↓
ORNBV.FI
52.44
-0.19%↓
SAN
103.98
+0.48%↑
SHL.DE
55.4
+0.54%↑
PHIA
24.26
+0.96%↑
SRT3
241.7
-2.89%↓
ORNBV.FI
52.44
-0.19%↓
SAN
103.98
+0.48%↑
SHL.DE
55.4
+0.54%↑
PHIA
24.26
+0.96%↑
SRT3
241.7
-2.89%↓
ORNBV.FI
52.44
-0.19%↓
SAN
103.98
+0.48%↑
SHL.DE
55.4
+0.54%↑
PHIA
24.26
+0.96%↑
SRT3
241.7
-2.89%↓
ORNBV.FI
52.44
-0.19%↓
SAN
103.98
+0.48%↑
SHL.DE
55.4
+0.54%↑
PHIA
24.26
+0.96%↑
SRT3
241.7
-2.89%↓
ORNBV.FI
52.44
-0.19%↓
24h
Current
Min
135.1
Max
135.65
Income | 202M 809M |
---|---|
Sales | -194M 5.3B |
P/E Sector Avg | 26.27 73.394 |
EPS | 2.2 |
Dividend yield | 1.34 |
Profit margin | 15.363 |
EBITDA | 85M 1.6B |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +30.26 upside |
Dividend yield Sector Avg | 1.34% 3.09% |
---|---|
Next Earnings | 6 Mar 2025 |
Market Cap | 33B 98B |
---|---|
Previous open | 136.2 |
Previous close | 135.5 |
By Trading Central
Confidence
Strong Bearish Evidence
134.7 / 135.55 Support & Resistance
Past performance is not a reliable indicator of future results.
11 Feb 2025, 07:03 UTC
Germany's Merck in Talks to Buy SpringWorks Therapeutics
DJ
Read
10 Feb 2025, 16:38 UTC
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
DJ
Read
14 Nov 2024, 08:09 UTC
Merck KGaA Earnings Growth Beats Expectations -- Update
DJ
Read
14 Nov 2024, 06:26 UTC
Merck KGaA Expects Sales at Lower End of Outlook Range After Third-Quarter Miss
DJ
Read
11 Feb 2025, 16:45 UTC
Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk
DJ
Read
11 Feb 2025, 10:54 UTC
Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk
DJ
Read
11 Feb 2025, 10:52 UTC
German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk
DJ
Read
6 Jan 2025, 13:08 UTC
Merck KGaA: Transaction closed on Dec. 23, 2024
DJ
Read
6 Jan 2025, 13:07 UTC
Merck KGaA: Didn't Disclose Financial Details
DJ
Read
6 Jan 2025, 13:06 UTC
Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio
DJ
Read
6 Jan 2025, 13:04 UTC
Merck KaA Acquires HUB Organoids Holding B.V. to Expand Its Next-Generation Biology Portfolio
DJ
Read
17 Dec 2024, 13:05 UTC
Merck: Deal Expected to Close By End Dec. 2024
DJ
Read
17 Dec 2024, 13:04 UTC
Merck: Terms of Deal Undisclosed
DJ
Read
17 Dec 2024, 13:04 UTC
Merck Signs Pact to Buy HUB Organoids
DJ
Read
17 Dec 2024, 13:03 UTC
Merck: Acquisition Advances Next Gen Biology Portfolio
DJ
Read
17 Dec 2024, 13:03 UTC
Merck to Buy HUB Organoids Holding
DJ
Read
14 Nov 2024, 11:15 UTC
Merck KGaA's Sales Target Dragged by Muted China Outlook -- Market Talk
DJ
Read
14 Nov 2024, 10:45 UTC
Merck KGaA's Life-Science Sales Recovery Is Encouraging -- Market Talk
DJ
Read
14 Nov 2024, 09:26 UTC
Merck KGaA's Electronics Division Disappointed -- Market Talk
DJ
Read
14 Nov 2024, 06:00 UTC
Merck KGaA Sees 2024 EBITDA Before One-Time Items Around Mid-Point Of Range
DJ
Read
14 Nov 2024, 06:00 UTC
Merck KGaA Had Seen 2024 Net Sales Between EUR20.7B and EUR22.1B
DJ
Read
14 Nov 2024, 06:00 UTC
Merck KGaA 3Q EBITDA EUR1.55B .
DJ
Read
14 Nov 2024, 06:00 UTC
Merck KGaA Sees 2024 EPS Pre Around Mid-Point of EUR8.20 to EUR9.30
DJ
Read
14 Nov 2024, 06:00 UTC
Analysts Saw Merck KGaA 3Q Ebitda Before One-Time Items at EUR1.55B
DJ
Read
14 Nov 2024, 06:00 UTC
Merck KGaA Backs 2024 View
DJ
Read
14 Nov 2024, 06:00 UTC
Merck KGaA 3Q Sales EUR5.27B
DJ
Read
14 Nov 2024, 06:00 UTC
Analysts Saw Merck KGaA 3Q Net Sales at EUR5.33B
DJ
Read
14 Nov 2024, 06:00 UTC
Merck KGaA: 3Q Life Science Returns to Organic Sales Growth
DJ
Read
14 Nov 2024, 06:00 UTC
Merck KGaA Had Seen 2024 EBITDA Before One-Time Items Between EUR5.8B to EUR6.4B
DJ
Read
14 Nov 2024, 06:00 UTC
Merck KGaA Expects 2024 Net Sales In Lower Half Of Range
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 176.5 EUR 30.26%
High 190 EUR
Low 160 EUR
Based on 8 Wall Street analysts offering 12 month price targets forMerck KGaA - Dist in the last 3 months.
By TipRanks
Strong Buy
8 ratings
6
Buy
2
Hold
0
Sell
Based on 8 analysts giving stock ratings to Merck KGaA - Dist in the past 3 months.
By Trading Central
Short Term
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Long Term
Strong Bearish Evidence
All events are bearish.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$